Barrington sets USD 2.25 target for OPKO Health stock

Published on 10/17/2026 at 18:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 4.30 percent to USD 163.58 million in the second quarter. OPKO Health stock was USD 1.53 on October 16, 2026, down 4.97 percent versus the Nasdaq close.

Analyst target and financial position

Barrington Research set a USD 2.25 target for OPKO Health on October 16, 2026.
Revenue rose 4.30 percent to USD 163.58 million in the second quarter of 2026.
OPKO Health stock was USD 1.53 at 4:00 p.m. ET on October 16, 2026, down 4.97 percent versus the Nasdaq close of October 15, 2026.
OPKO Health had a USD 1.1 billion market capitalization as of October 16, 2026.

OPK, US68375N1037, Illustration mit AI erstellt.

MarketBeat reported on October 16, 2026 that Barrington Research upgraded OPKO Health from Market Perform to Outperform and set a USD 2.25 price target. Against the USD 1.53 Nasdaq price, that target stood 47.06 percent higher. OPKO Health stock was last at USD 1.53 on October 16, 2026 at 4:00 p.m. ET, down 4.97 percent versus the Nasdaq close of October 15, 2026.

Revenue improved in the second quarter

OPKO Health reported revenue of USD 163.58 million for the second quarter of 2026, up 4.30 percent from the year-ago quarter, according to the company's investor-relations information. The company also posted a consolidated net loss of USD 8.42 million and diluted loss per share of USD 0.01 for the period ended June 30, 2026. Those figures compare with a USD 0.19 loss per share in the second quarter of 2025, while the loss narrowed to USD 8.42 million from the prior-year level.

The improvement in revenue and earnings per share gives the analyst upgrade a measurable operating backdrop. OPKO's business combines diagnostics through BioReference Laboratories with pharmaceuticals and a development pipeline, leaving the USD 2.25 target dependent on execution beyond the second quarter.

Stock remains below its yearly high

The USD 1.53 Nasdaq price stood USD 0.24 below OPKO's USD 1.77 52-week high and USD 0.55 above its USD 0.98 52-week low as of October 16, 2026. The stock was therefore 13.56 percent below the high and 56.12 percent above the low. The market capitalization was USD 1.1 billion on the same date.

OPKO's valuation metrics remain shaped by losses. The latest quoted price-to-earnings ratio was negative 16.04, while the company reported a negative operating result of USD 6.97 million for the second quarter of 2026. The operating cash flow for that period was negative USD 43.50 million, adding a cash-generation factor to the target discussion.

Comparison with peers

OPKO: minus 4.97 percent, P/E negative 16.04, market capitalization USD 1.1 billion.

Labcorp Holdings (NYSE, USD): minus 2.19 percent, P/E 26.30, market capitalization USD 25.8 billion.

Quest Diagnostics (NYSE, USD): minus 1.74 percent, P/E 24.95, market capitalization USD 25.9 billion.

Analyst target sets the next benchmark

Barrington's USD 2.25 target is the clearest near-term benchmark in the latest coverage, but the distance to that level is material. OPKO's second-quarter revenue growth offers support for the target, while the negative operating result and negative cash flow show why execution remains central to the valuation.

OPKO Health is headquartered in Miami and operates across diagnostics and pharmaceuticals. Its investor-relations page lists the second-quarter 2026 results and the October 15, 2026 Labcorp agreement as recent company updates, while the analyst action arrived on October 16, 2026.

Nasdaq price and valuation

OPKO Health stock was last at USD 1.53 on October 16, 2026 at 4:00 p.m. ET, down 4.97 percent versus the Nasdaq close of October 15, 2026. The stock remained 13.56 percent below its USD 1.77 52-week high, with a USD 1.1 billion market capitalization.